Asha B Thomas

Dr. Asha B Thomas


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2020 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
ASAaftab S. Shaikh
Aaftab S. Shaikh
ATAsha B Thomas
Asha B Thomas
SCSohan S. Chitlange
Sohan S. Chitlange

28 April 2021 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
ATArchana K. Thikekar
Archana K. Thikekar
ATAsha B Thomas
Asha B Thomas
SCSohan S. Chitlange
Sohan S. Chitlange

23 November 2021 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
PKPrajakta B. Kothawade
Prajakta B. Kothawade
ATAsha B Thomas
Asha B Thomas
SCSohan Chitlange
Sohan Chitlange
Background: Hyperlipidemia is characterized by high level of cholesterol and triglycerides in blood. Various classes of drugs like statins, fibrates, niacin etc. are used for treatment of hyperlipidaemia. Objective: Niacin, which is one of the beneficial anti-hyperlipidemic agents, helps to lower LDL cholesterol by 20 to 40% and causes increase of HDL cholesterol by 20 to 35%. However cutaneous flushing, loss of glucose tolerance, liver toxicity are the reported side effects of niacin therapy responsible for decreased patient compliance. Very recently, the G protein coupled receptor (GPCR); GPR109A located on the adipocytes has been identified as the receptor for activation of niacin. Method: In-vitro studies have demonstrated that GPR109A receptor having high affinity for niacin. The present review attempts to provide a systematic presentation of the various chemical classes of compounds that have been reported as novel niacin receptor agonists including pyrazole-3-carboxylic acids, urea derivatives, anthranilic acids, biaryl anthranilides, tetrahydro anthranilic acid, xanthines, barbituric acid, bicyclic pyrazole carboxylic acids, pyrido pyrimidinones, pyrazolyl propionyl cyclohexenamides, pyrazole acids etc. Results: As the design of GPR109A receptor agonists offers a promising solution for treatment of dyslipidemia, this review will be beneficial for medicinal and drug discovery chemists to expediate the process of discovery of new class of antihyperlipidemic agent with favorable lipid lowering profile with increase in HDL levels. Conclusion: This review explains about novel GPR109A receptor agonist for the treatment of dyslipidemia.

1 April 2020 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
ATAsha B Thomas
Asha B Thomas
AKAbhilash Kanakdhar
Abhilash Kanakdhar
ASAdinath Shirsat
Adinath Shirsat
SDSanjeevani Shekhar Deshkar
Sanjeevani Shekhar Deshkar
LKLata Kothapalli
Lata Kothapalli
A systematic design of experiment (DoE) based sensitive, robust high performance thin layer chromatographic (HPTLC) method was established for simultaneous estimation of gallic acid (GA), quercetin (QT), and rutin (RT) from ethanolic and aqueous leaf extracts of Moringa oleifera. The chromatographic separation was carried on Merck TLC aluminum sheets of silica gel 60 F254 (10×10 cm) with mobile phase of toluene: ethyl acetate: methanol: formic acid (4.9:4.1:2:0.5, v/v/v/v) with densitometric scanning at 300 nm. The critical method parameters were initially identified by regular two level factorial design and further systematically optimized using a central composite design, evaluating the effect on selected critical analytical attributes, retention factor (RF), and peak area. The Pareto charts, 3D response surface plots, and polynomial equations for the generated models suggested significant influence of the selected factors on responses of QT, GA, and RT. The desirability and overlay plots employed provided appropriate solutions that were experimentally validated. Under the optimized conditions, the biomarkers were suitably resolved with RF values of 0.64±0.02, 0.80±0.03, and 0.22±0.02 for GA, QT, and RT, respectively, with wide linear dynamic range (200-1200 ng/band each), high accuracy (98.1-99.4%), and intra- and interday precision (%RSD <2%). When employed for quantification of these biomarkers in Moringa oleifera extracts, the ethanolic and aqueous extracts exhibited higher content of QT (993.5 μg/g and 832 μg/g, respectively). The ethanolic extract showed a larger amount of RT (701 μg/g). In contrast, aqueous extract exhibited a higher proportion of GA (591.1 μg/g) compared to ethanolic extract (150 μg/g). This validated HPTLC method developed through a DoE approach was successfully employed for quantification of GA, QT, and RT from Moringa oleifera extracts and may also be extended for their simultaneous estimation in other herbal extracts, thereby reducing time, and may serve as a cost effective tool for analysis.

11 March 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PJPranali A. Jadhav
Pranali A. Jadhav
ATAsha B Thomas
Asha B Thomas
MPMohsin K. Pathan
Mohsin K. Pathan
SCSomdatta Y. Chaudhari
Somdatta Y. Chaudhari
RWRavindra D. Wavhale
Ravindra D. Wavhale
SCSohan S. Chitlange
Sohan S. Chitlange
Liver diseases account for over two million deaths annually, amounting to 4% of mortality worldwide, underscoring the need for development of novel preventive and therapeutic strategies. The growing interest in natural hepatoprotective agents highlights the potential of traditional medicine for modern drug discovery, though unlocking their molecular complexity requires advanced tools. This study integrates cutting-edge computational techniques with traditional herbal knowledge to identify potential hepatoprotective compounds. Protein targets implicated in liver disorders were identified through network pharmacology and by leveraging the rich molecular diversity inherent in herbal compounds, phytocompounds were selected. The Gene Ontology, Kyoto Encyclopedia of Genes and Genome data were compiled and enrichment analysis was performed using the DAVID database. Molecular docking of selected phytocompounds with top five protein targets helped identify 14 compounds which were employed for building the pharmacophore model. In virtual screening, among 1089 compounds screened, 10 compounds were identified as potential hits based on their predicted scores and alignment with pharmacophore features. The interactions of resulting hits were then analyzed through redocking studies and validated through molecular dynamics simulation and ADMET studies. Notably, (2S,5E)-2-(3,4-Dihydroxybenzyl)-6-(3,4-dihydroxyphenyl)-4-oxo-5-hexenoic acid and 5′-hydroxymorin emerged as lead compounds for further investigation. Both compounds exhibited significant binding affinities with specific amino acids in selected targets, suggesting their potential to modulate key pathways involved in hepatic disorders. Our findings demonstrate the utility of this integrated approach which transits beyond traditional trial-and-error methods. This approach will accelerate the discovery of novel hepatoprotective compounds, providing deeper insights into their mechanistic pathways and action.

1 April 2024 in Egyptian Liver Journal
Verified
Journal Article
Open access
PDF file
PJPranali A. Jadhav
Pranali A. Jadhav
ATAsha B Thomas
Asha B Thomas
RNRabindra K. Nanda
Rabindra K. Nanda
SCSohan S. Chitlange
Sohan S. Chitlange
A prevalent liver condition called non-alcoholic fatty liver disease (NAFLD) may progress into non-alcoholic steatohepatitis (NASH) and cause life-threatening complications like cirrhosis and liver cancer. The development and progression of NAFLD has been linked to the make-up and functioning of the gut microflora. This article reviews the clinical studies reported to investigate the connection between changes in the gut microbiota and metabolic markers in NAFLD patients. According to the study findings, dysbiosis of the gut microflora were observed in NAFLD patients, which are manifested by variations in the proportions of particular bacterial species. These changes are linked to fibrosis, liver inflammation, and metabolic abnormalities. The article also discusses various treatments targeting the gut microbiota, including dietary modifications, exercise, prebiotics, probiotics, synbiotics, antibiotics, and fecal microbiota transplantation. These therapies are intended to enhance NAFLD outcomes and reestablish the healthy gut microflora. While some studies have shown promising results, further research is needed to establish the optimal approaches, long-term safety, and efficacy of these treatments for NAFLD.